Literature DB >> 10421914

In vivo magnetic resonance spectroscopy of human fetal neural transplants.

B D Ross1, T Q Hoang, S Blüml, D Dubowitz, O V Kopyov, D B Jacques, A Lin, K Seymour, J Tan.   

Abstract

To better define the survival and cellular composition of human fetal neurotransplants in vivo, we performed quantitative 1H MRS to determine the concentration of the neuronal amino acid [N-acetylaspartate] within MRI-visible grafts. In all, 71 grafts in 38 patients [24 Parkinson's disease (PD), 14 Huntington's disease (HD)] were examined, as well as 24 untreated PD and HD patients and 13 age-matched normal controls. MRI appearances of edema were present in three out of 71 grafts, the remainder being consistent with histologically identified viable neural transplant tissue. N-acetylaspartate (NAA), creatine, choline, myoinositol and glutamine plus glutamate (Glx) were identified in all post-transplant putamens, with abnormal metabolites, lactate and/or lipid detectable in only three patients. Of 71 grafts, 19 occupied more than 60% of the MRS-examined volume (VOI) (mean 84.2 +/- 3%; range 61-100%). In those, [NAA] was 8.50 +/- 0.99 mM in eight PD spectra and 6.59 +/- 0.81 mM in 11 HD spectra, and was not significantly different from controls. In contrast, transplanted fetal neurones contain less than 0.4 mM of the neuronal amino acid NAA. This suggests that established fetal neurotransplants in the human putamen of both PD and HD patients are populated by adult neurones, axons and dendrites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421914     DOI: 10.1002/(sici)1099-1492(199906)12:4<221::aid-nbm582>3.0.co;2-q

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  12 in total

1.  Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.

Authors:  A E Rosser; R A Barker; T Harrower; C Watts; M Farrington; A K Ho; R M Burnstein; D K Menon; J H Gillard; J Pickard; S B Dunnett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

Review 2.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 3.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 4.  Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.

Authors:  Alexander Lin; Brian D Ross; Kent Harris; Willis Wong
Journal:  NeuroRx       Date:  2005-04

Review 5.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

6.  Molecular imaging of cell transplantation in Parkinson's disease.

Authors:  Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04       Impact factor: 9.236

7.  A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions.

Authors:  C Dirk Keene; Rubens C Chang; James B Leverenz; Oleg Kopyov; Susan Perlman; Robert F Hevner; Donald E Born; Thomas D Bird; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2008-12-05       Impact factor: 17.088

Review 8.  Cell therapy in Huntington's disease.

Authors:  Stephen B Dunnett; Anne E Rosser
Journal:  NeuroRx       Date:  2004-10

Review 9.  Clinical imaging in regenerative medicine.

Authors:  Anna V Naumova; Michel Modo; Anna Moore; Charles E Murry; Joseph A Frank
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 68.164

Review 10.  Emerging Imaging Modalities in Regenerative Medicine.

Authors:  Mitchel R Stacy; Albert J Sinusas
Journal:  Curr Pathobiol Rep       Date:  2015-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.